PAPILLOMAVIRAL CARCINOGENESIS. MAJOR ACHIEVEMENTS AND CERTAIN CHALLENGES PART 2. HPV-ASSOCIATED CANCERS IN RUSSIA. PREVENTIVE HPV VACCINES

Cervical cancer (CC) incidence rate made up about 5 % in overall women cancer incidence in Russia in 2015. CC morbidity rose by 24.47 % during 2005–2015. Despite the fact that aggregated standardized cancer mortality rates for both men and women during 2005–2015 declined, women CC mortality increased by 8.3 %. CC is the leading cancer mortality cause in women aged 30–39 years. Moreover growth of oral and pharynx cancer incidence rates in both genders as well as penile cancer in men all indicate to an unfavorable trend. The present Review part contains data on HPV-associated cancers in Russia, vertical HPV transition as well as preventive HPV vaccines.

[1]  G. Volgareva.  PAPILLOMAVIRAL CARCINOGENESIS. MAJOR ACHIEVEMENTS AND CERTAIN CHALLENGES PART I. GENERAL NOTIONS OF PAPILLOMAVIRUSES. HUMAN PAPILLOMAVIRUSES-ASSOCIATED CANCERS , 2020, Russian Journal of Biotherapy.

[2]  G. Volgareva,et al.  Detection of human papillomavirus type 18 oncogen E7 in patients with prostate cancer , 2019, Russian Journal of Biotherapy.

[3]  G. Volgareva.  Natural history of papillomaviruses in men – what is known? , 2018, Russian Journal of Biotherapy.

[4]  Hafiz M.N. Iqbal,et al.  Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus , 2018, Front. Immunol..

[5]  S. Syrjänen,et al.  HPV infection and bacterial microbiota in breast milk and infant oral mucosa , 2018, PloS one.

[6]  S. Syrjänen,et al.  HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa , 2018, Scientific Reports.

[7]  K. Looker,et al.  Evidence of synergistic relationships between HIV and Human Papillomavirus (HPV): systematic reviews and meta‐analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status , 2018, Journal of the International AIDS Society.

[8]  S. Garland,et al.  Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries , 2018, The Journal of infectious diseases.

[9]  F. Coutlée,et al.  Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada , 2018, Human vaccines & immunotherapeutics.

[10]  D. Spandidos,et al.  HPV vaccination in boys: Determining the clinical relevance of this strategy , 2017, Experimental and therapeutic medicine.

[11]  J. Kim,et al.  HPV prevalence in the foreskins of asymptomatic healthy infants and children: Systematic review and meta-analysis , 2017, Scientific Reports.

[12]  G. Zimet,et al.  The feminization of HPV: How science, politics, economics and gender norms shaped U.S. HPV vaccine implementation , 2017, Papillomavirus research.

[13]  S. H. van der Burg,et al.  The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization , 2017, European Journal of Clinical Microbiology & Infectious Diseases.

[14]  A. Giuliano,et al.  Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial , 2016, The Journal of infectious diseases.

[15]  H. Trottier,et al.  Human papillomavirus (HPV) perinatal transmission and risk of HPV persistence among children: Design, methods and preliminary results of the HERITAGE study , 2016, Papillomavirus research.

[16]  V. Matveev,et al.  Loss of Cell Differentiation in HPV-Associated Bladder Cancer , 2016, Bulletin of Experimental Biology and Medicine.

[17]  M. Klemp,et al.  HPV catch-up vaccination of young women: a systematic review and meta-analysis , 2014, BMC Public Health.

[18]  J. Dillner,et al.  Expressed Prostate Secretions in the Study of Human Papillomavirus Epidemiology in the Male , 2013, PloS one.

[19]  L. Laimins,et al.  Viral transformation of epithelial cells. , 2013, Methods in molecular biology.

[20]  M. Pawlita,et al.  Human papillomavirus genotypes present in the oral mucosa of newborns and their concordance with maternal cervical human papillomavirus genotypes. , 2012, The Journal of pediatrics.

[21]  J. Dillner,et al.  Monitoring of human papillomavirus vaccination , 2011, Clinical and experimental immunology.

[22]  S. Grénman,et al.  Human papillomavirus in the placenta and umbilical cord blood , 2008, Acta obstetricia et gynecologica Scandinavica.

[23]  S. Grénman,et al.  High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV Family Study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  L. Laimins,et al.  Differentiation of HPV-containing cells using organotypic "raft" culture or methylcellulose. , 2005, Methods in molecular medicine.

[25]  S. Pagliusi,et al.  Efficacy and other milestones for human papillomavirus vaccine introduction. , 2004, Vaccine.

[26]  D. Lowy,et al.  Chapter 16: Prophylactic human papillomavirus vaccines. , 2003, Journal of the National Cancer Institute. Monographs.

[27]  F. Kisseljov,et al.  HPV infection in cervical‐cancer cases in Russia , 1995, International journal of cancer.